Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Properties of factor IX concentrates

E Berntorp1

  • 1Department for Coagulation Disorders, Malmö University Hospital, Sweden.

Acta Haematologica
|January 1, 1995
PubMed
Summary

Five purified factor IX concentrates demonstrate high specific activity and safety in hemophilia B patients. These products show comparable pharmacokinetic profiles to prothrombin complex concentrates, with no adverse effects observed during surgical cover or immune tolerance induction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Fifth Åland Island conference on von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Replacement therapy during surgery in von Willebrand disease needs personalization.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Defining extended half-life rFVIII-A critical review of the evidence.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Immune tolerance induction: What have we learned over time?

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Hemophilia B treatment relies on factor IX concentrates.
  • Prothrombin complex concentrates (PCCs) carry risks due to multiple coagulation factors.
  • Purified factor IX concentrates offer a more targeted therapeutic approach.

Purpose of the Study:

  • To biochemically characterize and evaluate the in vivo pharmacokinetic and thrombogenic properties of five purified factor IX concentrates.
  • To compare these purified concentrates with two PCCs.
  • To assess the safety and efficacy of purified factor IX concentrates in clinical applications like surgery and immune tolerance induction.

Main Methods:

  • Biochemical characterization of factor IX concentrates and PCCs.
  • In vivo pharmacokinetic studies in severe hemophilia B patients.
  • Evaluation of thrombogenic indicators (thrombin generation).

Main Results:

  • Purified concentrates showed high specific activity (50-100 fold higher than PCCs) and were devoid of other coagulation factors and inhibitors.
  • Pharmacokinetic profiles were comparable between Nanotiv, Preconativ, and Mononine.
  • Immunine and Prothromplex TIM4 showed lower recovery rates and shorter half-lives, potentially due to methodological differences.
  • No adverse effects were observed during surgical cover or immune tolerance induction.

Conclusions:

  • Purified factor IX concentrates are biochemically distinct and possess higher specific activity than PCCs.
  • These concentrates demonstrate acceptable pharmacokinetic profiles and a favorable safety profile for hemophilia B management.
  • Successful clinical use in surgical cover and immune tolerance induction supports their therapeutic value.

Related Experiment Videos